首页 / 产品 / 抗体 / 一抗

Rabbit Polyclonal Cleaved-PlasmaKallikreinHC(R390) Antibody

  • 中文名: Cleaved-Plasma Kallikrein HC (R390)抗体
  • 别    名: KLKB1; KLK3; Plasma kallikrein; Fletcher factor; Kininogenin; Plasma prekallikrein
货号: IPDX43016
Price: ¥1280
数量:
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 1/100 Human,Mouse,Rat
IHC 1/100-1/300 Human,Mouse,Rat
ICC 技术咨询 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 1/10000 Human,Mouse,Rat

产品详情

AliasesKLKB1; KLK3; Plasma kallikrein; Fletcher factor; Kininogenin; Plasma prekallikrein
Entrez GeneID3818;
WB Predicted band size45kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenSynthesized peptide derived from the Internal region of human Plasma Kallikrein HC.
FormulationPurified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol.

+ +

参考文献

以下是3篇与Cleaved-Plasma Kallikrein HC (R390)抗体相关的文献摘要,基于公开研究整理:

---

1. **Title**: *Structural characterization of activated plasma kallikrein in hereditary angioedema*

**Authors**: Smith A, et al.

**Summary**: 研究利用R390抗体通过Western blotting检测血浆激肽释放酶(Plasma Kallikrein)的活化形式(HC结构域),揭示了其在遗传性血管性水肿患者中的异常激活机制,证明该抗体对酶原裂解后的构象变化具有特异性识别能力。

---

2. **Title**: *Plasma kallikrein-mediated bradykinin release in sepsis: A role for R390-reactive antibodies*

**Authors**: Chen L, et al.

**Summary**: 通过ELISA和免疫组化实验,验证R390抗体可选择性识别脓毒症患者血浆中裂解的激肽释放酶活性片段(HC结构域),并发现其与缓激肽通路激活及血管通透性增加密切相关,为炎症疾病生物标志物研究提供工具。

---

3. **Title**: *Development of a cleavage-specific monoclonal antibody for plasma kallikrein activation studies*

**Authors**: Johnson R, et al.

**Summary**: 研究团队开发了R390单克隆抗体,通过质谱分析证实其特异性靶向激肽释放酶重链(HC)的R390位点裂解产物,可用于检测体外模型和病理样本中激肽系统的活化状态,为血栓和炎症研究提供新方法。

---

注:以上为模拟文献摘要,实际文献需通过PubMed/Google Scholar检索关键词“Plasma Kallikrein HC R390 antibody”或联系抗体供应商(如Cell Signaling Technology)获取应用文献。

背景信息

The Cleaved-Plasma Kallikrein HC (R390) antibody specifically detects the activated form of plasma kallikrein, a serine protease central to the contact activation system (CAS) and inflammatory pathways. Plasma kallikrein circulates as an inactive zymogen (plasma prekallikrein) bound to high-molecular-weight kininogen (HK). Upon activation via factor XIIa or other triggers, it undergoes proteolytic cleavage at Arg390-Ile391. releasing a heavy chain (HC) and a catalytic light chain (LC). The R390 antibody targets the neoepitope generated at the cleavage site (Arg390) on the HC, enabling selective detection of the enzymatically active form. This antibody is widely used to study kallikrein's role in coagulation, fibrinolysis, inflammation, and hereditary angioedema (HAE), where dysregulated kallikrein activity drives bradykinin-mediated vascular permeability. It helps identify pathological kallikrein activation in clinical samples or experimental models, offering insights into disease mechanisms and therapeutic interventions targeting the contact system. Validation typically includes Western blotting, immunohistochemistry, and ELISA, with specificity confirmed using recombinant proteins or knockout controls.

客户数据及评论

折叠内容

大包装询价

×